N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide

Catalog No. :
ACIEMW498
CAS No. :
60320-32-3
Molecular Formula :
C4H4ClN3OS
Molecular Weight :
177.62

IUPAC Name:N-(5-chloro-1,3,4-thiadiazol-2-yl)acetamide

N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$93.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-(5-Chloro-1,3,4-thiadiazol-2-yl)acetamide
IUPAC NameN-(5-chloro-1,3,4-thiadiazol-2-yl)acetamide
MDL No.MFCD00723607
Molecular FormulaC4H4ClN3OS
Molecular Weight177.62
SMILESCC(NC1=NN=C(Cl)S1)=O
InChI KeyCKUUONNLVFAZNC-UHFFFAOYSA-N
Synonym2-(AcetylaMino)-5-chloro-1,3,4-thiadiazole;2-AcetaMido-5-chloro-1,3,4-thiadiazole;2-AMino-5-acetaMido-1,3,4-thiadiazole;N-(5-Chloro-1,3,4-thiadiazol-2-yl)acetaMide;Acetazolamide EP Impurity A;Acetazolamide Impurity 1(Acetazolamide EP Impurity A);Acetamide,N-(5-chloro-1,3,4-thiadiazol-2-yl)-;Acetazolamide EP IMP A
CAS No.60320-32-3
PubChem CID314332

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301-H311-H331
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACIEMW498 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRMQV316 route compound structure diagram
    ACRMQV31637566-40-8 In Stock
  4. Then
  5. ACIEMW498 route product structure diagram
    ACIEMW49860320-32-3 In Stock
Inquiry

2. ACIEMW498 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRMQV316 route compound structure diagram
    ACRMQV31637566-40-8 In Stock
  4. Then
  5. ACIEMW498 route product structure diagram
    ACIEMW49860320-32-3 In Stock
Inquiry

Comments (0)